Evidence map›Paper›PMID 32319494›Full record

ReviewNatural product reports2020

Perspectives from nearly five decades of total synthesis of natural products and their analogues for biology and medicine.

K C Nicolaou, Stephan Rigol

Abstract readReview
In one paragraph

Review in Natural product reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Late-Stage Diversification: A Motivating Force in Organic Synthesis.Journal of the American Chemical Society · 2021
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

K C NicolaouDepartment of Chemistry, Rice University, 6100 Main Street, Houston, Texas 77005, USA. kcn@rice.edu.
Stephan Rigol

Funding

Small Molecules and Targeted Gene Delivery in Tumor AngiogenesisP01CA078045 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BOGER, DALE L · 1998 to 2008
$10.2M
TOTAL SYNTHESIS OF THIOSTREPTONR01AI055475 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NICOLAOU, K. C. · 2002 to 2014
$7.0M
TOTAL SYNTHESIS OF AZASPIRACIDSR01ES013314 · NIEHS · SCRIPPS RESEARCH INSTITUTE, THE · PI NICOLAOU, K. C. · 2005 to 2011
$3.1M
TOTAL SYNTHESIS OF KINAMYCINS AND LOMAIVITICINSR01CA100101 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI NICOLAOU, K. C. · 2006 to 2010
$2.5M
Enabling Technologies for Combinatorial ChemistryR01GM063752 · NIGMS · SCRIPPS RESEARCH INSTITUTE · PI NICOLAOU, K. C. · 2002 to 2005
$1.3M
NCI NIH HHS P01 CA078045NCI NIH HHS R01 CA100101NIAID NIH HHS R01 AI055475NIEHS NIH HHS R01 ES013314NIGMS NIH HHS R01 GM063752
6 · The paper itself

Abstract

Covering: 1970 to 2020By definition total synthesis is the art and science of making the molecules of living Nature in the laboratory, and by extension, their analogues. Although obvious, its application to the synthesis of molecules for biology and medicine was not always the purpose of total synthesis. In recent years, however, the field has acquired momentum as its power to reach higher molecular complexity and diversity is increasing, and as the demand for rare bioactive natural products and their analogues is expanding due to their recognised potential to facilitate biology and drug discovery and development. Today this component of total synthesis endeavors is considered highly desirable, and could be part of interdisciplinary academic and/or industrial partnerships, providing further inspiration and momentum to the field. In this review we provide a brief historical background of the emergence of the field of total synthesis as it relates to making molecules for biology and medicine. We then discuss specific examples of this practice from our laboratories as they developed over the years. The review ends with a conclusion and future perspectives for natural products chemistry and its applications to biology and medicine and other added-value contributions to science and society.

Indexed as

Biological ProductsDrug DiscoveryMolecular StructureBiological Products

Identifiers

PMID32319494
PMCPMC7578074

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.